Plain-English translation of NCT06472661 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a new combination treatment for advanced melanoma made up of two parts: focused ultrasound ablation (FUSA), which uses sound waves to safely heat and destroy tumor tissue, and an injection of (an experimental drug that activates your immune system). The treatment would be given about three weeks before your planned melanoma surgery, and researchers want to learn whether it's safe and how it affects the tumor.
Current treatments for advanced melanoma don't work for everyone, and researchers are looking for new ways to boost the body's natural ability to fight cancer cells. This trial combines a new physical treatment with an immune-boosting medication to see if together they can help prepare the tumor for surgery and improve outcomes.
You likely qualify if…
You likely don't qualify if…
You would visit the University of Virginia Medical Center for the experimental treatment, which happens about three weeks before your scheduled melanoma surgery. During your visit, you would receive sedation and then have the focused ultrasound procedure applied to one or two tumors to heat and destroy the tissue. After the ultrasound, you would receive a single injection of the experimental medication directly into one tumor. You may also have ultrasound images taken to measure how stiff or flexible your tumor is, and possibly a small tissue sample (biopsy) taken before or after treatment to help researchers understand how the treatment affected your cancer cells.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States